Glucocorticoid-Associated Osteonecrosis in Children with Acute Lymphoblastic Leukemia: Risk Factors, Diagnosis, and Management: A Narrative Review
DOI:
https://doi.org/10.12775/JEHS.2026.95.76675Keywords
acute lymphoblastic leukemia, ALL, glucocorticoids, osteonecrosis, magnetic resonance imaging, childAbstract
Introduction. Osteonecrosis (ON) is a disabling complication of childhood acute lymphoblastic leukemia (ALL) therapy, especially in adolescents. Glucocorticoid exposure is central to its development, but individual susceptibility and other treatment-related factors also contribute. MRI enables early detection, although prediction of lesion progression and optimal management remain challenging.
Aim. To summarize current evidence on glucocorticoid-associated ON in childhood ALL, focusing on risk factors, diagnosis, prevention, management, and long-term outcomes.
Material and methods. Narrative, non-systematic review of English-language publications identified in PubMed/MEDLINE and Google Scholar from January 2000 to September 2026. Cohort and case-control studies, randomized trials, systematic reviews, meta-analyses, guidelines, and consensus statements were considered, prioritizing pediatric ALL and recent evidence.
Results. Age ≥10 years and adolescence are the most consistent risk factors. Sex, glucocorticoid schedule and exposure, asparaginase, treatment intensity, metabolic abnormalities, and genetic susceptibility may further modify risk. MRI is the most sensitive method for early and multifocal disease, but lesion evolution is heterogeneous and evidence does not support universal screening. Intermittent dexamethasone scheduling may reduce ON risk in selected settings. No universally accepted management pathway exists; many lesions remain stable or resolve, whereas advanced articular disease may lead to collapse, surgery, and persistent functional impairment.
Conclusions. A risk-adapted strategy combining clinical surveillance, selective MRI, optimized treatment exposure, rehabilitation, and multidisciplinary care appears most appropriate. Prospective studies are needed to identify lesions at highest risk of progression and determine whether earlier intervention can prevent collapse and long-term disability.
References
1. Inaba H, Teachey D, Annesley C, Batra S, Beck J, Colace S, et al. Pediatric acute lymphoblastic leukemia, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(2):41-62. https://doi.org/10.6004/jnccn.2025.0006
2. Mulrooney DA, Hyun G, Ness KK, Bhakta N, Pui CH, Ehrhardt MJ, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol. 2019;6(6):e306-e316. https://doi.org/10.1016/S2352-3026(19)30050-X
3. Kunstreich M, Kummer S, Laws HJ, Borkhardt A, Kuhlen M. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016;101(11):1295-305. https://doi.org/10.3324/haematol.2016.147595
4. Jones LC, Kaste SC, Karol SE, DeFeo B, Kim HKW, Neel MD, et al. Team approach: management of osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67(11):e28509. https://doi.org/10.1002/pbc.28509
5. de Villiers N, Éthier C, Laverdière C, Alos N, Tran TH, Pelland-Marcotte M. Incidence and risk factors of serious osteonecrosis in pediatric acute lymphoblastic leukemia: a CYP-C population-based study. Pediatr Blood Cancer. 2026;73(6):e70271. https://doi.org/10.1002/1545-5017.70271
6. Mattano LA, Devidas M, Loh ML, Raetz EA, Chen Z, Winick NJ, et al. Development of osteonecrosis and improved survival in B-ALL: results of Children’s Oncology Group trial AALL0232. Leukemia. 2024;38(2):258-65. https://doi.org/10.1038/s41375-023-02099-1
7. Arnold K, Ronceray L, Benesch M, Crazzolara R, Dworzak M, Engstler G, et al. Incidence and risk factors of symptomatic osteonecrosis in children with acute lymphoblastic leukemia- a population-based analysis of the Austrian ALL-BFM Study Group. eJHaem. 2026;7(2):e70263. https://doi.org/10.1002/jha2.70263
8. Brivio E, Cossio A, Borra D, Silvestri D, Prunotto G, Colombini A, et al. Osteonecrosis in paediatric acute lymphoblastic leukaemia: incidence, risk factors, radiological patterns and evolution in a single-centre cohort. Br J Haematol. 2022;197(5):602-8. https://doi.org/10.1111/bjh.18147
9. Mogensen SS, Harila-Saari A, Mäkitie O, Myrberg IH, Niinimäki R, Vestli A, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(10):e27300. https://doi.org/10.1002/pbc.27300
10. Rokkanen R, Aarnivala H, Huhtaniska S, Palmu S, Pokka T, Pöyhönen T, et al. Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL 2008 protocol. Br J Haematol. 2025;207(5):1912-9. https://doi.org/10.1111/bjh.70085
11. Kaste SC, Pei D, Cheng C, Neel MD, Bowman WP, Ribeiro RC, et al. Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids. J Clin Oncol. 2015;33(6):610-5. https://doi.org/10.1200/JCO.2014.57.5480
12. Kuhlen M, Kunstreich M, Krull K, Meisel R, Borkhardt A. Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge. Blood Adv. 2017;1(14):981-94. https://doi.org/10.1182/bloodadvances.2017007286
13. Brochu A, Kairy D, Alos N, Laverdière C, Sinnett D, Sultan S, et al. Physical impairments, activity limitations, and participation restrictions of childhood acute lymphoblastic leukemia survivors with and without hip osteonecrosis: a PETALE cohort study. J Cancer Surviv. 2025;19(5):1739-49. https://doi.org/10.1007/s11764-024-01585-4
14. Girard P, Auquier P, Barlogis V, Contet A, Poiree M, Demeocq F, et al. Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood. Haematologica. 2013;98(7):1089-97. https://doi.org/10.3324/haematol.2012.081265
15. DeFeo BM, Kaste SC, Li Z, Brinkman TM, Neel MD, Srivastava DK, et al. Long-term functional outcomes among childhood survivors of cancer who have a history of osteonecrosis. Phys Ther. 2020;100(3):509-22. https://doi.org/10.1093/ptj/pzz176
16. Mattano LA, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906-15. https://doi.org/10.1016/S1470-2045(12)70274-7
17. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117(8):2340-7. https://doi.org/10.1182/blood-2010-10-311969
18. van Atteveld JE, de Groot-Kruseman HA, Fiocco M, Lequin MH, Neggers SJCMM, Pluijm SMF, et al. Effect of post consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols. Haematologica. 2021;106(4):1198-201. https://doi.org/10.3324/haematol.2020.257550
19. Abaji R, Gagné V, Espagne É, Alos N, Del Vecchio V, Ait Said L, et al. Genetic determinants of treatment-related bone toxicity in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther. 2026;120(3):786-94. https://doi.org/10.1002/cpt.70371
20. Zhu Q, Nambiar R, Schultz E, Gao X, Liang S, Flamand Y, et al. Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia. Br J Haematol. 2024;205(5):1889-98. https://doi.org/10.1111/bjh.19696
21. Yang W, Devidas M, Liu Y, Smith C, Dai Y, Winick N, et al. Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood. 2021;137(11):1550-2. https://doi.org/10.1182/blood.2020008471
22. Krull K, Kunstreich M, Bronsema A, Bleckmann K, Classen CF, Erdlenbruch B, et al. Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy. Leuk Lymphoma. 2019;60(1):78-84. https://doi.org/10.1080/10428194.2018.1466292
23. Smith GB, Pham NS, Alayleh A, Smith S, Chao K, Goodman SB, et al. Risk factors for corticosteroid-associated osteonecrosis in children: a national database study. J Pediatr Orthop Soc North Am. 2025;12:100199. https://doi.org/10.1016/j.jposna.2025.100199
24. Liu C, Janke LJ, Kawedia JD, Ramsey LB, Cai X, Mattano LA, et al. Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse model. PLoS One. 2016;11(3):e0151433. https://doi.org/10.1371/journal.pone.0151433
25. Toksvang LN, Andrés-Jensen L, Rank CU, Niinimäki R, Nersting J, Nielsen SN, et al. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemother Pharmacol. 2021;88(5):911-7. https://doi.org/10.1007/s00280-021-04316-z
26. Valtis YK, Place AE, Silverman LB, Vrooman LM, DeAngelo DJ, Luskin MR. Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. Br J Haematol. 2022;198(3):421-30. https://doi.org/10.1111/bjh.18093
27. Zhou R, Bian Y, Cai X, Sun H, Lv Z, Xu Y, et al. Advances in the mechanism for steroid-induced osteonecrosis of the femoral head. Bone Res. 2026;14(1):23. https://doi.org/10.1038/s41413-025-00477-2
28. Laumann RD, Pedersen LL, Andrés-Jensen L, Mølgaard C, Schmiegelow K, Frandsen TL, et al. Hyperlipidemia in children and adolescents with acute lymphoblastic leukemia: a systematic review and meta-analysis. Pediatr Blood Cancer. 2023;70(12):e30683. https://doi.org/10.1002/pbc.30683
29. Mogensen SS, Schmiegelow K, Grell K, Albertsen BK, Wehner PS, Kampmann P, et al. Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia. Haematologica. 2017;102(5):e175–e178. https://doi.org/10.3324/haematol.2016.160507
30. Motta F, Timilsina S, Gershwin ME, Selmi C. Steroid-induced osteonecrosis. J Transl Autoimmun. 2022;5:100168. https://doi.org/10.1016/j.jtauto.2022.100168
31. Hoo CP, Leung AW, Chan JP, Cheung YT, Cheng FW, Chow TT, et al. The incidence, risk factors, and outcomes of symptomatic avascular necrosis of bone among Chinese pediatric patients with acute lymphoblastic leukemia. Cancer Med. 2023;12(9):10315-25. https://doi.org/10.1002/cam4.5762
32. Barzilai-Birenboim S, Yacobovich J, Zalcberg Y, Arad-Cohen N, Avrahami G, Gilad G, et al. Bone pain at leukemia diagnosis and other risk factors for symptomatic osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021;68(8):e29033. https://doi.org/10.1002/pbc.29033
33. te Winkel ML, Pieters R, Hop WCJ, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29(31):4143-50. https://doi.org/10.1200/JCO.2011.37.3217
34. Valtis YK, Stevenson KE, Place AE, Silverman LB, Vrooman LM, Gotti G, et al. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL consortium trials. Blood Adv. 2022;6(1):72-81. https://doi.org/10.1182/bloodadvances.2021005278
35. Niinimäki T, Harila-Saari A, Niinimäki R. The diagnosis and classification of osteonecrosis in patients with childhood leukemia. Pediatr Blood Cancer. 2015;62(2):198-203. https://doi.org/10.1002/pbc.25295
36. Niinimäki T, Niinimäki J, Halonen J, Hänninen P, Harila-Saari A, Niinimäki R. The classification of osteonecrosis in patients with cancer: validation of a new radiological classification system. Clin Radiol. 2015;70(12):1439-44. https://doi.org/10.1016/j.crad.2015.08.011
37. Alayleh A, Naz H, Taylor V, Johnson TR, Farook S, Hofmann G, et al. Retrospective analysis and characterization of avascular necrosis by bone location in pediatric leukemia/lymphoma patients. J Pediatr Orthop. 2025;45(7):e641–e647. https://doi.org/10.1097/BPO.0000000000002963
38. Nielsen CG, Als-Nielsen B, Albertsen BK, Davídsson ÓB, Dimitrijevic A, Hjalgrim H, et al. Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1-45 years: a Danish cohort study. Leukemia. 2026;40(3):630-7. https://doi.org/10.1038/s41375-026-02873-x
39. te Winkel ML, Pieters R, Wind EJD, Bessems JH, van den Heuvel-Eibrink MM. Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica. 2014;99(3):430-6. https://doi.org/10.3324/haematol.2013.095562
40. Daneshdoost SM, El Abiad JM, Ruble KJ, Jones LC, Crane JL, Morris CD, et al. Bisphosphonate therapy for treating osteonecrosis in pediatric leukemia patients: a systematic review. J Pediatr Hematol Oncol. 2021;43(3):e365–e370. https://doi.org/10.1097/MPH.0000000000001793
41. Utriainen P, Niinimäki TT, Huurre AJ, Vepsäläinen KL, Mäkitie OM, Niinimäki RA. Bisphosphonate treatment in children with acute lymphoblastic leukemia and osteonecrosis-radiological and clinical findings in a national cohort. Acta Oncol. 2021;60(9):1140-5. https://doi.org/10.1080/0284186X.2021.1950928
42. Janke LJ, Kim J, Payton MA, Jenkins DA, Cai X, Finch ER, et al. Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models. Pediatr Blood Cancer. 2021;68(10):e29183. https://doi.org/10.1002/pbc.29183
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Oliwia Puła, Karolina Kuczyńska , Klaudia Ganczarenko, Marta Zielińska, Damian Lipiński, Natalia Miszkin , Zuzanna Łysoń, Zofia Klata, Martyna Wolniak, Maja Przenajkowska

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 2
Number of citations: 0